813424-51-0Relevant articles and documents
Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists
Oka, Hiromasa,Yonezawa, Koichi,Kamikawa, Akio,Ikegai, Kazuhiro,Asai, Norio,Shirakami, Shohei,Miyamoto, Satoshi,Watanabe, Toshihiro,Kiso, Tetsuo,Takemoto, Yukihiro,Tamura, Seiji,Kuramochi, Takahiro
, p. 3716 - 3726 (2018)
A new series of transient receptor potential vanilloid type 1 (TRPV1) antagonists were designed and synthesized from N-(3-hydroxyphenyl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide hydrochloride (8). SAR studies identified (R)-N-(1-methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide hydrochloride (ASP8370, 7), as a compound with high aqueous solubility, satisfactory stability in human liver microsomes, and reduced CYP3A4 inhibition. ASP8370 was selected as a clinical development candidate with significant ameliorative effects on neuropathic pain. SAR studies also revealed the structural mechanisms underlying the switching between TRPV1 antagonism and agonism.